Astellas U.S. Priorities Are Oncology Expansion, BD – President Robinson
Executive Summary
Astellas Pharma US expects oncology will account for 40% of sales in three years, becoming its top business segment – significant growth for a company that just four years ago had no commercial presence in oncology. The plans rely heavily on Xtandi, suggesting it might be time to ramp up business development activity.
You may also be interested in...
October Podcast: Ebola, Biosimilars, Astellas, CLL
Topics in the October “Pinkcast” include Ebola products, biosimilars marketing, Astellas in the U.S., and our market snapshot of chronic lymphocytic leukemia drugs.
PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).